Want to see SE:ALZCUR full AI Analyst Report?

AlzeCure Pharma AB (ALZCUR) Price & Analysis

0 Followers

ALZCUR Stock Chart & Stats

kr2.44

kr0.16(7.05%)

At close: Mar 06 4:00 PM EST

kr2.44

kr0.16(7.05%)

Day’s Range― - ―

52-Week Rangekr1.14 - kr8.06

Previous CloseN/A

Volume72.39K

Average Volume (3M)52.87K

Market Cap

kr849.45M

Enterprise Valuekr453.76M

Total Cash (Recent Filing)kr32.97M

Total Debt (Recent Filing)kr2.29M

Price to Earnings (P/E)―

Beta0.19

Next Earnings

Aug 26, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.53

Shares Outstanding137,897,340

10 Day Avg. Volume28,042

30 Day Avg. Volume52,872

Financial Highlights & Ratios

PEG Ratio-1.96

Price to Book (P/B)6.11

Price to Sales (P/S)0.00

P/FCF Ratio-5.81

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.35

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage / Balance Sheet ResilienceReported low trailing leverage provides durable financial flexibility: with modest debt relative to equity the company faces lower interest and refinancing pressure, enabling it to fund R&D via partnerships or targeted raises and retain negotiating power with collaborators.

R&D/partnering Business ModelA structure centered on discovery and out-licensing is a sustainable model for a small biotech: it aligns large upside to successful programs while avoiding the need for commercial infrastructure. Milestones, royalties and partner-funded development reduce long-term fixed-cost burdens.

CNS-focused Discovery PlatformsSpecialization in CNS small-molecule programs and proprietary discovery platforms creates structural optionality: multiple candidates and platform outputs raise the probability of a partnerable asset, concentrate technical expertise, and enhance appeal to larger pharma seeking CNS assets.

Bears Say

No Revenue; Persistent Large LossesThe company has no commercial revenue and sustained substantial losses, meaning it cannot self-fund development. Persistent unprofitability forces dependence on external capital, limits strategic flexibility, and raises execution risk over the medium term if financings weaken.

Heavy Cash BurnLarge and sustained negative operating and free cash flow create continual financing needs. This increases likelihood of dilutive equity raises or hurried partnerships, risks delaying programs if funding gaps emerge, and concentrates risk around capital markets access.

Erosion Of Equity / Shrinking Capital BufferSignificant depletion of equity reduces the company’s capital cushion against trial setbacks or prolonged development timelines. A smaller capital base heightens refinancing pressure and dilution risk, weakening resilience to adverse clinical or regulatory outcomes over the medium term.

ALZCUR FAQ

What was AlzeCure Pharma AB’s price range in the past 12 months?

AlzeCure Pharma AB lowest stock price was kr1.14 and its highest was kr8.06 in the past 12 months.

What is AlzeCure Pharma AB’s market cap?

AlzeCure Pharma AB’s market cap is kr849.45M.

When is AlzeCure Pharma AB’s upcoming earnings report date?

AlzeCure Pharma AB’s upcoming earnings report date is Aug 26, 2026 which is in 42 days.

How were AlzeCure Pharma AB’s earnings last quarter?

AlzeCure Pharma AB released its earnings results on May 05, 2026. The company reported -kr0.165 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.165.

Is AlzeCure Pharma AB overvalued?

According to Wall Street analysts AlzeCure Pharma AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does AlzeCure Pharma AB pay dividends?

AlzeCure Pharma AB does not currently pay dividends.

What is AlzeCure Pharma AB’s EPS estimate?

AlzeCure Pharma AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does AlzeCure Pharma AB have?

AlzeCure Pharma AB has 137,897,340 shares outstanding.

What happened to AlzeCure Pharma AB’s price movement after its last earnings report?

AlzeCure Pharma AB reported an EPS of -kr0.165 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.049%.

Which hedge fund is a major shareholder of AlzeCure Pharma AB?

Currently, no hedge funds are holding shares in SE:ALZCUR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

AlzeCure Pharma AB

AlzeCure Pharma AB (publ) operates as a pharmaceutical company that develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involved in the development of drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its products pipeline includes ACD856 for the treatment of Alzheimer’s disease, sleep disorders, depression, traumatic brain injuries, and Parkinson’s disease, which is in phase I clinical trial; ACD857, ACD679, and ACD680 that are in preclinical trial for the treatment of Alzheimer’s disease; ACD440, a TRPV1 antagonist that has completed phase I clinical trial for neuropathic pain indications; and ACD137, negative allosteric modulator (NAM) of TrkA receptors for osteoarthritic pain indications. The company was founded in 2012 and is based in Huddinge, Sweden.